Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma.
Michael O
MO
Idowu
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D066246:ErbB Receptors / Q000276:immunology*; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000592:standards*; D009154:Mutation / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D018631:ras Proteins / Q000235:genetics*
D000888:Antibodies, Anti-Idiotypic; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D018631:ras Proteins